Combined inhibition of MEK and mammalian target of rapamycin abolishes phosphorylation of cyclin-dependent kinase 4 in glioblastoma cell lines and prevents their proliferation

Cancer Research

Volumn 69, Issue 11, 2009, Pages 4577-4581

  Paternot, Sabine ^a   Roger, Pierre P ^a  

^a UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 CHLORO 4 IODOANILINO) N CYCLOPROPYLMETHOXY 3,4 DIFLUOROBENZAMIDE; CYCLIN D; CYCLIN D3; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE INHIBITOR 1B; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE; RAF PROTEIN; RAPAMYCIN; RAS PROTEIN; RETINOBLASTOMA PROTEIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; COMPETITIVE INHIBITION; DRUG POTENTIATION; ENZYME INHIBITION; GLIOBLASTOMA; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION;

BENZAMIDES; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE 4; DNA REPLICATION; DRUG COMBINATIONS; DRUG EVALUATION, PRECLINICAL; GLIOBLASTOMA; HUMANS; MAP KINASE KINASE 1; MAP KINASE KINASE 2; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; PROTEINS; RETINOBLASTOMA PROTEIN; SIROLIMUS; TRANSCRIPTION FACTORS; TUMOR CELLS, CULTURED;

EID: 66349086978     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-08-3260     Document Type: Article

References (23)

1. Rinehart J, Adjei AA, Lorusso PM, et al. Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer. J Clin Oncol 2004;22:4456-4462 (Pubitemid 41185111)
2. Reardon DA, Rich JN, Friedman HS, Bigner DD. Recent advances in the treatment of malignant astrocytoma. J Clin Oncol 2006;24:1253-1265 (Pubitemid 46622028)
3. Kohno M, Pouyssegur J. Targeting the ERK signaling pathway in cancer therapy. Ann Med 2006;38:200-211 (Pubitemid 43675585)
4. Sabatini DM. mTOR and cancer: insights into a complex relationship. Nat Rev Cancer 2006;6:729-734 (Pubitemid 44286004)
5. Sathornsumetee S, Rich JN. Designer therapies for glioblastoma multiforme. Ann N Y Acad Sci 2008;1142:108-132
6. Sherr CJ, McCormick F. The RB and p53 pathways in cancer. Cancer Cell 2002;2:103-112 (Pubitemid 41039110)
7. Lavoie JN, L'Allemain G, Brunet A, Muller R, Pouyssegur J. Cyclin D1 expression is regulated positively by the p42/p44MAPK and negatively by the p38/HOGMAPK pathway. J Biol Chem 1996;271:20608-20616 (Pubitemid 26281839)
8. Squires MS, Nixon PM, Cook SJ. Cell-cycle arrest by PD184352requir es inhibition of extracellular signal-regulated kinases (ERK) 1/2bu t not ERK5/BMK1. Biochem J 2002;366:673-680 (Pubitemid 35001712)
9. Tetsu O, McCormick F. Proliferation of cancer cells despite CDK2 inhibition. Cancer Cell 2003;3:233-245 (Pubitemid 37443879)
10. Hleb M, Murphy S, Wagner EF, et al. Evidence for cyclin D3 as a novel target of rapamycin in human T lymphocytes. J Biol Chem 2004;279:31948-31955 (Pubitemid 39037869)
11. Motti ML, De Marco C, Califano D, et al. Loss of p27 expression through RAS->BRAF->MAP kinase-dependent pathway in human thyroid carcinomas. Cell Cycle 2007;6:2817-2825 (Pubitemid 350277175)
12. Lee YM, Sicinski P. Targeting cyclins and cyclin-dependent kinases in cancer: lessons from mice, hopes for therapeutic applications in human. Cell Cycle 2006;5:2110-2114 (Pubitemid 44553745)
13. Bockstaele L, Coulonval K, Kooken H, Paternot S, Roger PP. Regulation of CDK4. Cell Division 2006;1:25. (Pubitemid 46731032)
14. Bockstaele L, Kooken H, Libert F, et al. Regulated activating Thr172 phosphorylation of cyclin-dependent kinase 4(CDK4): its relationship with cyclins and CDK "inhibitors". Mol Cell Biol 2006;26:5070-5085
15. Paternot S, Coulonval K, Dumont JE, Roger PP. Cyclic AMP-dependent phosphorylation of cyclin D3-bound CDK4 determines the passage through the cell cycle restriction point in thyroid epithelial cells. J Biol Chem 2003;278:26533-40.
16. Rocha AS, Paternot S, Coulonval K, Dumont JE, Soares P, Roger PP. Cyclic AMP inhibits the proliferation of thyroid carcinoma cell lines through regulation of CDK4 phosphorylation. Mol Biol Cell 2008;19:4814-4825
17. Kato JY, Matsuoka M, Polyak K, Massague J, Sherr CJ. Cyclic AMP-induced G1 phase arrest mediated by an inhibitor (p27Kip1) of cyclin-dependent kinase 4 activation. Cell 1994;79:487-496 (Pubitemid 124000770)
18. Matsuoka M, Kato JY, Fisher RP, Morgan DO, Sherr CJ. Activation of cyclin-dependent kinase 4 (cdk4) by mouse MO15-associated kinase. Mol Cell Biol 1994;14:7265-7275 (Pubitemid 24326391)
19. Fisher RP. Secrets of a double agent: CDK7 in cell-cycle control and transcription. J Cell Sci 2005;118:5171-5180 (Pubitemid 41819581)
20. Costa LJ, Gemmill RM, Drabkin HA. Upstream signaling inhibition enhances rapamycin effect on growth of kidney cancer cells. Urology 2007;69:596-602. (Pubitemid 46428416)
21. Legrier ME, Yang CP, Yan HG, et al. Targeting protein translation in human non small cell lung cancer via combined MEK and mammalian target of rapamycin suppression. Cancer Res 2007;67:11300-11308 (Pubitemid 350248556)
22. Lasithiotakis KG, Sinnberg TW, Schittek B, et al. Combined inhibition of MAPK and mTOR signaling inhibits growth, induces cell death, and abrogates invasive growth of melanoma cells. J Invest Dermatol 2008;128:2013-2023
23. Hjelmeland AB, Lattimore KP, Fee BE, et al. The combination of novel low molecular weight inhibitors of RAF (LBT613) and target of rapamycin (RAD001) decreases glioma proliferation and invasion. Mol Cancer Ther 2007;6:2449-2457 (Pubitemid 47480410)